Breckenridge Pharmaceutical, Inc. drugs
6 results
Azelastine hydrochloride (azelastine hydrochloride)
(AZELASTINE HYDROCHLORIDE)Breckenridge Pharmaceutical, Inc.
Usage: Azelastine Hydrochloride Nasal Spray is indicated for treating seasonal allergic rhinitis symptoms in adults and children aged 5 and older, and vasomotor rhinitis symptoms in adults and adolescents aged 12 and older.
Dexrazoxane (dexrazoxane hydrochloride)
(Dexrazoxane Hydrochloride)Breckenridge Pharmaceutical, Inc.
Usage: Dexrazoxane for Injection is indicated to reduce cardiomyopathy risk in women with metastatic breast cancer who have received 300 mg/m² of doxorubicin and are continuing treatment. It is not to be used at the start of doxorubicin therapy.
Duloxetine (duloxetine hydrochloride)
(DULOXETINE HYDROCHLORIDE)Breckenridge Pharmaceutical, Inc.
Usage: Duloxetine delayed-release capsules are indicated for treating major depressive disorder, generalized anxiety disorder (in adults and children 7+), diabetic peripheral neuropathic pain, fibromyalgia (in patients 13+), and chronic musculoskeletal pain in adults.
Granisetron hydrochloride (granisetron hydrochloride)
(Granisetron Hydrochloride)Breckenridge Pharmaceutical, Inc.
Usage: Granisetron hydrochloride tablets are indicated for preventing nausea and vomiting related to emetogenic cancer therapy (including high-dose cisplatin) and radiation treatments, such as total body irradiation and fractionated abdominal radiation.
Oxcarbazepine (oxcarbazepine)
(OXCARBAZEPINE)Breckenridge Pharmaceutical, Inc.
Usage: Oxcarbazepine tablets are indicated for monotherapy or adjunctive therapy in treating partial-onset seizures in adults and pediatric patients aged 4 years and older. For pediatric patients aged 2 years and older, it is indicated as adjunctive therapy for partial-onset seizures.
Zolpidem tartrate (zolpidem tartrate)
(Zolpidem Tartrate)Breckenridge Pharmaceutical, Inc.
Usage: Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia, specifically targeting difficulties in sleep onset and maintenance, as assessed by wake time after sleep onset. Clinical trials support efficacy for up to 3 weeks.